Results for enoksaparina translation from Slovenian to English

40 mg enoksaparina primerljiv.
the main safety endpoint, major bleeding, showed comparable rates for patients treated with rivaroxaban 10 mg compared to enoxaparin 40 mg.

peroralna absorpcija enoksaparina ni verjetna.
the oral absorption of enoxaparin is unlikely.

ugotovili niso nobenih znakov teratogenih ali fetotoksičnih učinkov enoksaparina.
there was no evidence of teratogenic effects or foetotoxicity due to enoxaparin.

kaže, da je farmakokinetika enoksaparina v priporočenem območju odmerjanja linearna.
enoxaparin pharmacokinetics appears to be linear over the recommended dose ranges.

1 vključuje dogodke po prvem odmerku enoksaparina (pred operacijo).
1 includes events occurring after first dose of enoxaparin (pre-surgery)

znano je, da ti faktorji pripomorejo k celotnemu antitrombotičnemu učinku enoksaparina.
these factors are known to contribute to the overall anti-thrombotic effect of enoxaparin.

dolgoročne študije za oceno kancerogenega potenciala enoksaparina na živalih niso bile izvedene.
no long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin.

učinka fondaparinuksa in enoksaparina na pojavnost mi in ri se med skupinama nista statistično pomembno razlikovala.
the effects on the incidence of mi and ri were not statistically different between the fondaparinux and enoxaparin treatment groups.

učinka fondaparinuksa in enoksaparina na pojavnost mi in ri se med skupinama nista statistično pomembno razlikovala. ilo
mi and ri were not statistically different between the fondaparinux and enoxaparin treatment groups.

v vseh glavnih študijah je bilo zdravilo xarelto učinkovitejše od enoksaparina pri preprečevanju nastajanja krvnih strdkov in smrti.
in all of the main studies, xarelto was more effective than enoxaparin in preventing the formation of blood clots and death.

injekcije enoksaparina so prejemali do odpusta iz bolnišnice ali največ osem dni (kar je nastopilo prej).
injectable enoxaparin was administered until hospital discharge or for a maximum of 8 days (the incident which occurred earlier).

reproduction is authorised provided the source is acknowledged. bolnikih pettedensko jemanje zdravila xarelto primerjali z dvotedenskim jemanjem enoksaparina.
reproduction is authorised provided the source is acknowledged. two weeks of enoxaparin in around 2,500 patients undergoing knee replacement surgery.

po subkutanem injiciranju je absolutna biološka uporabnost enoksaparina, določena na podlagi aktivnosti xa, skoraj 100-odstotna.
the absolute bioavailability of enoxaparin after subcutaneous injection, based on anti-xa activity, is approximately 100%.

dokazali so, da zdravljenje s fondaparinuksom ni bilo slabše od enoksaparina (pogostosti vte 3,9 % oziroma 4,1
treatment with fondaparinux was demonstrated to be non-inferior to enoxaparin (vte rates 3.9% and 4.1%, respectively).

dodaten razmislek je zlasti potreben pri bolnikih s kreatininskim očistkom <30 ml/min, saj je pri njih izločanje enoksaparina podaljšano.
for patients with creatinine clearance <30 ml/minute, additional considerations are necessary because elimination of enoxaparin is more prolonged.

izsledki obeh raziskav so pokazali, da antitrombotični učinek zdravila pradaxa v odmerku 220 mg in 150 mg ni statistično manjši od učinka enoksaparina, če upoštevamo skupno pojavnost trombemboličnih dogodkov in umrljivost iz vseh vzrokov.
results of both studies showed that the antithrombotic effect of pradaxa 220 mg and 150 mg were statistically non-inferior to that of enoxaparin on total vte and all-cause mortality.

pri približno 20. 000 bolnikih z ua/ nstemi je primerjala uporabo fondaparinuksa v odmerku 2, 5 mg subkutano enkrat na dan in enoksaparina v odmerku 1 mg/ kg subkutano dvakrat na dan.
treatment of unstable angina or non-st segment elevation myocardial infarction (ua/ nstemi) oasis 5 was a double-blind, randomised, non-inferiority study with fondaparinux 2.5 mg subcutaneously once daily versus enoxaparin 1 mg/ kg subcutaneously twice daily in approximately 20,000 patients with ua/ nstemi.

pri približno 20. 000 bolnikih z lje ua/ nstemi je primerjala uporabo fondaparinuksa v odmerku 2, 5 mg subkutano enkrat na dan in enoksaparina v odmerku 1 mg/ kg subkutano dvakrat na dan.
all patients received standard medical treatment for ua/ nstemi,

ustrezne incidence pri bolnikih, ki so prejemali priporočeno shemo enoksaparina za zdravljenje dvt, so bile 2, 5%, 3, 6% oziroma 8, 3%, medtem ko so bile incidence pri bolnikih na priporočeni shemi ufh za zdravljenje pe, 5, 5%, 6, 6% oziroma 7, 4%.
26 corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of dvt were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of ufh in the treatment of pe were 5.5%, 6.6% and 7.4%, respectively.